IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL
Journal of Oncology · 10.01.2023 · 2023 · 1-7
DOI: 10.1155/2023/1388041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology, erschienen am 10.01.2023. Verfasst von Han-Bing Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical …. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation.
Abstract (Originalsprache)
Chemoresistance is a key obstacle in the clinical treatment and management of activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL), which leads to the poor prognosis of patients. Exploring novel biomarkers to early warn drug resistance and ameliorate the patients’ outcome in ABC-DLBCL is urgent and crucial. Previously, we found that insulin-like growth factor-binding protein 3 (IGFBP3) was remarkably associated with immunochemotherapy treatment response through microarray screening. Based on a retrospective cohort (n = 160) and a GEO cohort (n = 292), here we determined the positive expression rate of IGFBP3 and analyzed the role of IGFBP3 in treatment response and prognostics in ABC-DLBCL. The results demonstrated that the complete response (CR) rate of R-CHOP treatment was higher in ABC-DLBCL with IGFBP3 positive expression than those with IGFBP3 negative expression (42.0% vs 26.4%), and IGFBP3 positive expression in ABC-DLBCL was significantly correlated with enhanced therapeutic response (P = 0.037). High level of IGFBP3 was negatively correlated with tumorigenesis and development and predicted favorable survival time in ABC-DLBCL. In conclusion, IGFBP3 may be utilized as a promising biomarker for prognosis evaluation and a potential therapy target in ABC-DLBCL patients.
Autor:innen und Institutionen
- Department of Clinical Laboratory, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
- Department of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
- Center for Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
ORCID-Profile: Han-Bing Li, Di Wang, Yue Zhang, Di Shen, Yi-Qun Che
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Natural Science Foundation
Zitieren
APA
Li, H. B., Wang, D., Zhang, Y., Shen, D., & Che, Y. Q. (2023). IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL. Journal of Oncology, 2023, 1-7. https://doi.org/10.1155/2023/1388041
Vancouver
Li HB, Wang D, Zhang Y, Shen D, Che YQ. IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL. Journal of Oncology. 2023;2023:1-7. doi:10.1155/2023/1388041
BibTeX
@article{Li2023,
author = {Li, Han-Bing and Wang, Di and Zhang, Yue and Shen, Di and Che, Yi-Qun},
title = {IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL},
journal = {Journal of Oncology},
year = {2023},
volume = {2023},
pages = {1--7},
doi = {10.1155/2023/1388041}
}
EUVIMED